A randomized, double-blind, placebo-controlled, parallel-design, multicenter study to evaluate the urodynamic effects of tadalafil once a day for 12 weeks in men with signs and symptoms of benign prostatic hyperplasia

Trial Profile

A randomized, double-blind, placebo-controlled, parallel-design, multicenter study to evaluate the urodynamic effects of tadalafil once a day for 12 weeks in men with signs and symptoms of benign prostatic hyperplasia

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2013

At a glance

  • Drugs Tadalafil (Primary)
  • Indications Benign prostatic hyperplasia; Lower urinary tract symptoms
  • Focus Pharmacodynamics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 01 Mar 2010 Results have been published in the Journal of Urology.
    • 19 Jan 2010 Results were published in the Journal of Urology.
    • 19 Jan 2010 Primary endpoint 'Urinary parameters' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top